Skip to main content
. 2023 Apr 25;29(2):97–103. doi: 10.5114/pedm.2023.124266

Table II.

Comparison of anthropometric data between SH patients: non-treated (SH-T0) and treated with levothyroxine (SH-T1)

Parameter SH
(n= 130)
Mean ± SD
(median; IQR)
SH-T0 (n= 35) Mean ±SD (median; IQR) SH-T1 (n= 95) Mean ±SD (median; IQR) p-value (* significance between SH-T0 and SH-T1)
hSDS at baseline –0.1 ±1.6 (0.0; from –1.2 to 1.0) –0.3 ±1.4 (–0.4; from –1.4 to 0.6) 0.0±1.7 (0.2; from –1.1 to 1.2) 0.315
ΔhSDS 0.0±0.7 (0.1; from –0.3 to 0.5) 0.1 ±0.9 (0.2; from –0.2 to 0.4) 0.0 ±0.8 (0.1; from –0.3 to 0.5) 0.843
BMI Z-score at baseline 0.3 ±1.3 (0.2; from –0.9 to 1.3) 0.2 ±1.2 (0.2; from –0.5 to 1.0) 0.3 ±1.4 (0.3; from –0.9 to 1.4) 0.769
ΔBMI Z-score 0.0±0.6 (–0.1; from –0.4 to 0.2) 0.0 ±0.5 (0.0; from –0.4 to 0.3) 0.0 ±0.7 (0.1; from –0.4 to 0.2) 0.761

hSDS – height standard deviation score; BMI – body mass index; N – number; SD – standard deviation